Immunohistochemical analysis of bcl-2, bax, mcl-1, and bcl-X expression in ovarian surface epithelial tumors

International Journal of Gynecological Pathology

Volumn 17, Issue 3, 1998, Pages 255-260

  Wehrli, Bret M ^a   Krajewski, Stanislaw ^b   Gascoyne, Randy D ^a   Reed, John C ^b   Gilks, C Blake ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BURNHAM INSTITUTE   (United States)

Author keywords

Bax; Bcl 2; Immunohistochemistry; Ovarian surface epithelial tumors

Indexed keywords

ANALYTIC METHOD; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; EPITHELIUM TUMOR; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0031807774     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-199807000-00010     Document Type: Article

References (35)

1. Williams GT. Programmed cell death: apoptosis and oncogenesis. Cell 1991;65:1097-8.
2. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992;80:879-86.
3. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994;124:1-6.
4. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-62.
5. Reed JC. Double identity for proteins of the bcl-2 family. Nature 1997;387:773-6.
6. Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 1986;83:5214-8.
7. Oltvai Z, Milliman C, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programmed cell death. Cell 1993;74:609-19.
8. Boise LH, Gonzalez-Garcia M, Postema CE, et al. bcl-x, a bcl-2 related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993;74:597-608.
9. Reynolds JE, Yang T, Qian L, et al. Mcl-1, a member of the bcl-2 family, delays apoptosis induced by c-Myc overexpression in Chinese hamster ovary cells. Cancer Res 1994;54:6348-52.
10. McCluggage G, McBride H, Maxwell P, Bharucha H. Immunohistochemical detection of p53 and bcl-2 proteins in neoplastic and non-neoplastic endocervical glandular lesions. Int J Gynecol Pathol 1997;16:22-7.
11. Krajewska M, Krajewski S, Epstein JI, et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996;148:1567-76.
12. Nakamura T, Nomura S, Saki T, Nariya S. Expression of bcl-2 oncoprotein in gastrointestinal and uterine carcinomas and their premalignant lesions. Hum Pathol 1997;28:309-15.
13. Brown C, Sauvageot J, Kahane H, Epstein JI. Cell proliferation and apoptosis in prostate cancer-correlation with pathologic stage? Mod Pathol 1996;9:205-9.
14. Nakagawa K, Yamamura K, Maeda S, Ichihashi M. bcl-2 expression in epidermal keratinocytic diseases. Cancer 1994;74:1720-4.
15. Ben-Ezra JM, Komstein MJ, Grimes MM, Krystal G. Small cell carcinomas of the lung express the bcl-2 protein. Am J Pathol 1994;145:1036-40.
16. Pezzella F, Turley H, Kuzu I, et al. bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 1993;329:690-4.
17. Krajewska M, Fenoglio-Preiser CM, Krajewski S, et al. Immunohistochemical analysis of bcl-2 family proteins in adenocarcinomas of the stomach. Am J Pathol 1996;149:1449-57.
18. Chan WK, Mole MM, Lavison DA, et al. Nuclear and cytoplasmic bcl-2 expression in endometrial hyperplasia and adenocarcinoma. J Pathol 1995;177:241-6.
19. Herod JJO, Eliopoulos AG, Warwick J, Niedobitek G, Young LS, Kerr DJ. The prognostic significance of bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 1996;56:2178-84.
20. Diebold J, Baretton G, Felchner M, et al. bcl-2 expression, p53 accumulation and apoptosis in ovarian carcinomas. Am J Clin Pathol 1996;105:341-9.
21. Henriksen R, Wilander E, Öberg K. Expression and prognostic significance of bcl-2 in ovarian tumours. Br J Cancer 1995;72: 1324-9.
22. Eliopoulos A, Kerr DJ, Herod J, et al. The control of apoptosis and drug resistance in ovarian cancer-influence of p53 and bcl-2. Oncogene 1995;11:1217-28.
23. McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the proto-oncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992; 52:6940-4.
24. Flohil CC, Janssen PA, Bosman FT. Expression of Bcl-2 protein in hyperplastic polyps, adenomas and carcinomas of the colon. J Pathol 1996;178:393-8.
25. Serov SF, Scully RE, Sobin LH. International histological classification of tumors, No. 9. Histological typing of ovarian tumors. Geneva, World Health Organization, 1973.
26. Krajewski S, Bodrug S, Gascoyne RD, Berean K, Krajewska M, Reed JC. Immunohistochemical analysis of Mcl-1 and bcl-2 proteins in normal and neoplastic lymph nodes. Am J Pathol 1994; 145:515-25.
27. Krajewski S, Krajewska M, Shabaik A, et al. Immunohistochemical analysis of in vivo patterns of bcl-X expression. Cancer Res 1994;54:5501-7.
28. Krajewski S, Chatten J, Hanada M, Womer R, Reed JC. Immunohistochemical analysis of the bcl-2 oncoprotein in human neuroblastomas. Lab Invest 1994;72:42.
29. Krajewski S, Blomvqvist C, Franssila K, et al. Reduced expression of pro-apoptotic gene bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 1995;55:4471-8.
30. Bosman FT, Visser BC, van Overen J. Apoptosis: pathophysiology of programmed cell death. Path Rex Pract 1996;192:676-83.
31. Kerr KM, Lamb D. Actual growth rate and tumour cell proliferation in human pulmonary neoplasms. Br J Cancer 1984;50:343-9.
32. Kernohan NM, Cox LS. Regulation of apoptosis by bcl-2 and its related proteins: immunochemical challenges and therapeutic implications. J Pathol 1996;179:1-3.
33. Ohmori T, Podack ER, Nishio K, et al. Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT 11, ADM) is inhibited by bcl-2. Biochem Biophys Res Commun 1993;192:30-6.
34. Scully RE. Mucinous tumors. In: Scully RE (ed). Tumors of the ovary and maldeveloped gonads, 1979. Washington, DC: Armed Forces Institute of Pathology, 1979:75-91.
35. Pietenpol JA, Papadopoulos N, Markowitz S, Willson JKV, Kinzler KW, Vogelstein B. Paradoxical inhibition of solid tumor cell growth by bcl-2. Cancer Res 1994;79:189-92.